Entering text into the input field will update the search result below

Blue Chip DRiP Portfolio: February Dividend Income Review

Blue Chip DRiP profile picture
Blue Chip DRiP


  • Last week, the stock market pumped the brakes hard. On a sheet of ice. Where will this bus land and how many innocents will be taken out?
  • I'm not sure. But this I do know: Our February dividend income remained predictable and growing. We received $1621.34 from 19 different stocks. In addition, 9 dividend raises were announced.
  • All-time dividends received are up to $10,921.81 since we began this portfolio exactly one year ago. Happy one-year anniversary!
  • We made 16 cash buys, 2 DRiPs, and 1 sale in February. These transactions add $1,529.81 annually, bringing our total forward estimated annual dividend income to $17,657.65.

Payers Gonna Pay

As I sit down and pen, er, type this monthly portfolio review, the headlines read:

Source: Seeking Alpha

Fiscal fear is seeping into the atmosphere as our presidential election eeks closer. COVID-19. Bernie. Recession. The markets had their worst week since 2008. Crystal balls are working overtime. I told you so's are proudly stepping forward. But here's the thing. You keep extra water, batteries, and canned food in your pantry. You live debt free, below your means, pay yourself first. You have an emergency fund and dry powder ready to deploy at a moment's notice. You invest in high-quality, dividend-paying businesses with a long-term outlook. You are diversified. You are prepared financially and mentally for a recession. You are not forced to sell your stocks, nor does the thought even cross your mind. You stick to the plan through the ups and downs. As any hip-hop song from the 2000s will tell you, haters gonna hate. When there's fear, sellers gonna sell. With all this uncertainty, it's absolutely imperative to keep the emotions in check and stay the course. Don't stray. I don't know which way the wind will blow tomorrow, but I know one thing: Dividend payers gonna pay.

Source: TeeSpring

Dividend Income: 2020 (Blue) vs 2019 (Red)

In February 2020, we pocketed $1,621.34 of dividend income. There is no February 2019 data to compare it to, because the Blue Chip DRiP portfolio is barely a year old and didn't generate any income until March 2019. As the year moves on, it will be fun to see how this chart fills out YoY.

Dividend Income Received: February 2020

Ticker / Stock Name Income
AbbVie (ABBV) $155.22
Antero Midstream (AM) $206.03
Bristol-Myers Squibb (BMY) $20.40
Blackstone Group (BX) $49.08
Caterpillar (CAT) $30.90

This article was written by

Blue Chip DRiP profile picture
Long term, buy and hold kinda guy. My focus is receiving passive dividend income from high quality businesses that pay a solid yield and offer consistent dividend growth. My dad was a stock broker for 30+ years, and always preached the power of saving, compounding interest, and reinvesting dividends. Now he is retired with an ever-growing passive income, and I am trying to catch him. Husband and father of two (ages 11 and 6). Financial emancipation here we come!

Analyst’s Disclosure: I am/we are long EVERYTHING IN THIS PORTFOLIO. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This is not stock advice. These are purely my opinions. I'm not a professional. Do your own research. Best of luck in your investing journey!

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.